Alternative Endpoints in Phase III Trials Don’t Always Mean Boosts to OS, QOL

(MedPage Today) — CHICAGO — Late-phase trials that showed superiority for an experimental intervention on a surrogate endpoint did not necessarily lead to improvements in overall survival (OS) or quality of life (QOL), according to a meta-epidemiologic…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115842

Author :

Publish date : 2025-06-01 21:43:00

Copyright for syndicated content belongs to the linked Source.